Abstracts tagged "Autoantibodies and polymyositis/dermatomyositis (PM/DM)"

Abstract Number: 2060 • 2013 ACR/ARHP Annual Meeting
Influence Of Anti-Ro/SSA Autoantibodies On Cinical Characteristic Of a Cohort Of Myositis Patients
Simone Barsotti¹, Rossella Neri², Valentina Iacopetti³, Chiara Baldini², Nicoletta Luciano², Antonio Tavoni⁴, Anna d'Ascanio⁵ and Stefano Bombardieri⁶, ¹Rheumatology Unit, University of Pisa, Pisa, Italy, ²University of Pisa, Rheumatology Unit, Pisa, Italy, ³Internal medicine, Barga, Italy, ⁴University of Pisa, Immunoallergology Unit, Pisa, Italy, ⁵Malattie muscolo-scheletriche e cutanee, Rheumatology Unit, Pisa, Italy, ⁶Rheumatology Unit, Pisa, Italy
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of acquired diseases, characterized by immunoflogistic processes primarily involving the skeletal muscle. Myositis-associated antibodies are frequently detected…
Abstract Number: 223 • 2012 ACR/ARHP Annual Meeting
High Prevalence and Clustering Over Time of Anti-PL-7 Autoantibody-Positive Idiopathic Inflammatory Myopathies
Yoshioki Yamasaki¹, Minoru Satoh², Hidehiro Yamada¹, Machiko Mizushima¹, Takahiro Okazaki¹, Hiroko Nagafuchi¹, Seido Ooka³, Tomohiko Shibata¹, Hiromasa Nakano⁴, Hitoshi Ogawa¹, Kohei Azuma¹, Akihiko Maeda¹, Hirofumi Mitomi¹, Tomofumi Kiyokawa¹, Kosei Tsuchida¹, Hidenori Mikage¹, Jason Y.F. Chan² and Shoichi Ozaki¹, ¹Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ²Medicine, University of Florida, Gainesville, FL, ³St. Marianna University School of Medicine, Kawasaki, Japan, ⁴Division of Rheumatology and Allergy, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: Unusually high prevalence of autoantibodies to threonyl tRNA (PL-7) [17% in polymyositis/dermatomyositis (PM/DM) associated with lower levels of serum creatine kinase (CK) and milder…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].